Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.3 (
phospholipase C
)
18,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We studied the aggregating effect of different concentrations of
phospholipase C
(
PLC
) (extracted from Clostridium perfringens) on human platelet-rich plasma (PRP). PRP was preincubated with
PLC
for 3 min at 37 degrees C and the platelet aggregation was followed for 10 min. The threshold aggregating concentration (TAC) of
PLC
was 3-4 U/ml. We also studied the potentiation of
PLC
with other stimuli on platelet aggregation. Potentiating stimuli, such as arachidonic acid (AA), ADP.
Platelet Activating Factor
(
PAF
) and U-46619 (a stable analogue of cyclic endoperoxides) were all used at subthreshold concentrations. We also studied the possible inhibitory effect of aspirin, apyrase, TMQ, a prostaglandin endoperoxide/thromboxane receptor antagonist and BN-52021, a PAF receptor antagonist. Only aspirin and apyrase were able to reduce aggregation induced by
PLC
alone and
PLC
+ AA and
PLC
+ ADP respectively. TMQ and BN-52021 were inactive. In ex vivo experiments oral aspirin (500 mg) partially inhibited platelet aggregation induced by
PLC
alone,
PLC
+ AA and
PLC
+ ADP 2 and 24 h after administration. Aspirin 20 mg for 7 days also reduced aggregation induced by
PLC
+ AA.
...
PMID:Phospholipase C from clostridium perfringens induces human platelet aggregation in plasma. 289 18
